Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| TANDEM DIABETES (NASDAQ: TNDM) | Delayed: 19.05 +1.40 (7.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.65 | 52 Week High | $12.48 | |||
| Open | $17.83 | 52 Week Low | $1.60 | |||
| Day High | $19.29 | P/E | N/A | |||
| Day Low | $17.83 | EPS | $-6.33 | |||
| Volume | 3,714,648 | |||||
